Åke Borg

Research interests

Publications

• Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.

  Kölner Universitäts PublikationsServer (Universität zu Köln) · 2021 · https://doi.org/10.17863/cam.78454

• Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions

  Nature Communications · 2021 · 10.1038/s41467-021-26271-2

• Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

  Nature Genetics · 2020 · 10.1038/s41588-020-0609-2

• Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D

  JNCI Journal of the National Cancer Institute · 2020 · https://doi.org/10.1093/jnci/djaa030

• Integrating spatial gene expression and breast tumour morphology via deep learning

  Nature Biomedical Engineering · 2020 · 10.1038/s41551-020-0578-x

• High-definition spatial transcriptomics for in situ tissue profiling

  Nature Methods · 2019 · https://doi.org/10.1038/s41592-019-0548-y

• Cancer Risks Associated With GermlinePALB2Pathogenic Variants: An International Study of 524 Families

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.01907

• Somatic mutations reveal asymmetric cellular dynamics in the early human embryo

  Nature · 2017 · https://doi.org/10.1038/nature21703

• HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

  Nature Medicine · 2017 · https://doi.org/10.1038/nm.4292

• Visualization and analysis of gene expression in tissue sections by spatial transcriptomics

  Science · 2016 · https://doi.org/10.1126/science.aaf2403

• The topography of mutational processes in breast cancer genomes

  Nature Communications · 2016 · https://doi.org/10.1038/ncomms11383

• Landscape of somatic mutations in 560 breast cancer whole-genome sequences

  Nature · 2016 · https://doi.org/10.1038/nature17676

• Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease

  EMBO Molecular Medicine · 2015 · 10.15252/emmm.201404913

• Signatures of mutational processes in human cancer

  Nature · 2013 · 10.1038/nature12477

• The Life History of 21 Breast Cancers

  Cell · 2012 · https://doi.org/10.1016/j.cell.2012.04.023

• Mutational Processes Molding the Genomes of 21 Breast Cancers

  Cell · 2012 · https://doi.org/10.1016/j.cell.2012.04.024

• GOBO: Gene Expression-Based Outcome for Breast Cancer Online

  PLoS ONE · 2011 · 10.1371/journal.pone.0017911

• The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions

  British Journal of Cancer · 2008 · 10.1038/sj.bjc.6604305

• The CD44+/CD24-phenotype is enriched in basal-like breast tumors

  Breast Cancer Research · 2008 · https://doi.org/10.1186/bcr2108

• Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair

  Nature Genetics · 2007 · 10.1038/ng.2007.39

• Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity

  Proceedings of the National Academy of Sciences · 2007 · 10.1073/pnas.0702507104

• Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotype

  Cancer Cell · 2006 · https://doi.org/10.1016/j.ccr.2006.08.026

• PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma

  Cancer Research · 2005 · https://doi.org/10.1158/0008-5472-can-04-3913

• Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies

  The American Journal of Human Genetics · 2003 · 10.1086/375033

• BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data

  Genome biology · 2002 · 10.1186/gb-2002-3-8-software0003

• Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns.

  PubMed · 2001

• Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus

  Proceedings of the National Academy of Sciences · 2000 · https://doi.org/10.1073/pnas.97.17.9603

• Amplification and Deletion of Topoisomerase IIα Associate with ErbB-2 Amplification and Affect Sensitivity to Topoisomerase II Inhibitor Doxorubicin in Breast Cancer

  American Journal Of Pathology · 2000 · 10.1016/s0002-9440(10)64952-8

• Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families

  The American Journal of Human Genetics · 1998 · https://doi.org/10.1086/301749

• High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients.

  PubMed · 1996

• HER-2/neu amplification predicts poor survival in node-positive breast cancer.

  PubMed · 1990

Current projects

No projects listed.